Physician profile
Janey Phipps
NPI 1245328319
$5,295.19
in general payments reported to CMS, 2019-2025
37 companies · $795 in 2025
The $795 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $738 · 2022: $896 · 2023: $1,684 · 2024: $1,183 · 2025: $795.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,654 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,653.52 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $816.94 | 2021-2025 | |
| Novo Nordisk INC | $776.68 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $489.89 | 2021-2025 | Mounjaro, Jardiance, Trulicity |
| Biohaven Pharmaceuticals, INC. | $334.82 | 2021 | |
| Abbott Laboratories | $329.92 | 2023-2025 | Freestyle Libre 3, Cardiomems, Freestyle Libre 2 |
| Biohaven Pharmaceutical Holding Company LTD. | $299.74 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $253.27 | 2021-2025 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $240.74 | 2021-2025 | |
| Pfizer INC. | $225.90 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $178.11 | 2022-2023 | |
| Axsome Therapeutics, INC. | $156.43 | 2023-2024 | Auvelity |
| Janssen Pharmaceuticals, INC | $154.51 | 2021-2024 | Spravato |
| Phathom Pharmaceuticals, INC. | $145.55 | 2024-2025 | Voquezna |
| Amgen INC. | $136.41 | 2021-2024 | Otezla, Repatha |
| Glaxosmithkline, LLC. | $101.39 | 2021-2024 | Arexvy, Shingrix, Trelegy Ellipta |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $99.35 | 2024 | |
| Amarin Pharma, INC. | $84.97 | 2021-2022 | |
| Astellas Pharma US INC | $58.22 | 2021-2025 | Veozah |
| Sumitomo Pharma America, INC. | $45.75 | 2023 | Gemtesa |
| Ardelyx, INC. | $39.24 | 2025 | Ibsrela |
| Madrigal Pharmaceuticals | $32.72 | 2025 | Rezdiffra |
| Merck Sharp & Dohme LLC | $31.77 | 2021 | |
| Mylan Specialty L.P. | $25.57 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.42 | 2024 | Eohilia |
| Sanofi-Aventis U.S. LLC | $20.75 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $20.23 | 2024 | Dupixent |
| Gilead Sciences, INC. | $20.10 | 2025 | |
| Corcept Therapeutics | $19.20 | 2025 | Korlym |
| Aimmune Therapeutics, INC. | $18.71 | 2024 | |
| Dexcom, INC. | $17.57 | 2022 | |
| Radius Health, INC. | $16.14 | 2021 | |
| Lundbeck LLC | $15.35 | 2025 | Vyepti |
| Astrazeneca Pharmaceuticals LP | $15.26 | 2021 | |
| Genzyme Corporation | $13.72 | 2023 | |
| Idorsia Pharmaceuticals US INC | $12.71 | 2023 | Quviviq |
| Genentech USA, INC. | $12.14 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $12.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janey Phipps listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.